Skip to main content
CTKB logo

CTKB · Cytek Biosciences, Inc.

Track CTKB — free
$5.92 +0.22 (+3.86%) At close · Nov 18
Market Cap
$774.24M
Shares
130.78M
Volume · Nov 18 1.05M Avg daily vol (3M) 1.27M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.92 Open$5.68 Day$5.62–5.98 52W close$3.36–6.30 Avg vol 30d1.3M Short int4.1M · 3.1% of shares · 3.6d Short vol45% Last earningsNov 4, 2026 DataJul 2021–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 17
Investor event
Gross margin up 600 basis points on Singapore shift

Cytek's analyzer category sales were up more than 30% compared to a year ago, and gross margin improved 600 basis points from the Singapore manufacturing shift, lower tariffs and better material costs.

3 source passages
Our analyzer category, which is Aurora, Aurora Evo, and Borealis, was up more than 30% compared to a year ago. We completed the transition of manufacturing capacity from Seattle to Singapore, and finally have closed our manufacturing activities in Seattle. And together with lower tariffs and better material costs, the combination of those three gave us a 600 basis point improvement in gross margin. Open the document at this passage
Nov 4
Earnings call
Revenue rises 2% as gross margin reaches 59%

SciTech Biosciences reported third-quarter revenue of $53.2 million, up 2% year-over-year, and GAAP gross margin of 59%. Full-year 2026 revenue guidance was narrowed to $208 million to $211 million, with adjusted EBITDA expected around break-even.

4 source passages
third quarter revenue came in at $53.2 million, an increase of 2% compared to Q3 2025. GAAP gross profit of $31.2 million in Q3, representing a gross margin of 59% compared to 53% in Q3 2025. We are maintaining the midpoint of our full-year 2026 revenue guidance while narrowing the range to $208 million to $211 million. For the full year 2026, we continue to expect adjusted EBITDA to be around break-even Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grew 4%, but net loss widened

Cytek Biosciences reported nine-month revenue of $145.5 million, up 4%, while net loss widened to $37.1 million from $22.5 million; service revenue rose 13% and gross margin reached 56%.

Revenue $53.23M ▲ 1.8% Net loss $6.1M
Read from the MD&A section
5 source passages
Unless the context requires otherwise, references to “we,” “us” and “our” refer to Cytek Biosciences, Inc. Total revenue, net increased by $6.2 million to $145.5 million, or 4%, for the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025. Our net loss was $6.1 million and $37.1 million for the three and nine months ended September 30, 2026, respectively, and $5.5 million and $22.5 million for the three and nine months ended September 30, 2025, respectively. Service revenue increased $1.9 million to $16.1 million, or 13%, and by $5.3 million to $47.0 million, or 13%, for the three and nine months ended September 30, 2026, as compared to the three and nine months ended September 30, 2025, respectively. Total gross profit margin was 59% and 53% of total revenue for the three months ended September 30, 2026 and 2025, respectively, and 56% and 51% for the nine months ended September 30, 2026 and 2025, respectively. Open the document at this passage
Nov 4
Current report 8-K
Revenue rises 2% as gross margin reaches 59%

Cytek Biosciences reported third-quarter revenue of $53.2 million, up 2%, GAAP gross margin of 59% and a net loss of $6.1 million; full-year revenue guidance was narrowed to $208 million to $211 million.

Financial results
4 source passages
Total revenue for the third quarter of 2026 was $53.2 million, a 2% increase compared to the third quarter of 2025. GAAP gross profit margin was 59% in the third quarter of 2026 compared to 53% in the third quarter of 2025. Net loss in the third quarter of 2026 was $6.1 million, compared to a net loss of $5.5 million in the third quarter of 2025. Cytek Biosciences is maintaining the midpoint of its revenue outlook for the full year 2026 and narrowing the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates. Open the document at this passage
Sep 29
Current report 8-K Events of Sep 23
Charter or bylaw amendment, or fiscal year change

On September 23, 2026, Cytek Biosciences, Inc. adopted amended and restated bylaws, expanding proponent disclosure and certifications, incorporating universal proxy rules, and adding special-meeting nomination procedures.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$207.65M
Trailing 12 months
Net income (TTM)
−$81.20M
Trailing 12 months
Revenue growth YoY
+1.8%
Year over year
Operating margin
-21.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$66.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.2%
Year over year · more shares
Price change (1Y)
+7.1%
Trailing year
Short interest
3.1%
Latest settlement · 3.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Revenue guidance retained its midpoint, while gross margin expanded, high-end instrument demand remained strong and recurring revenue increased. APAC and biopharma sales declined, adjusted EBITDA fell, patent litigation remained unresolved, and the organizational restructuring was postponed.

Bullish
  • + GAAP gross margin increased to 59% from 53%, supported by higher product and service gross margins.
  • + Full-year 2026 revenue guidance retained its midpoint while the range narrowed to $208 million–$211 million.
  • + Demand for high-end Full Spectrum Profiling instruments remained strong, with Aurora and Aurora Evo placements up 23% year over year.
  • + Recurring revenue reached $19.1 million and increased to 36% of trailing-12-month revenue from 33%.
  • + The installed base expanded to 4,073 instruments after adding 140 units during the quarter.
  • + Management expects a seasonally stronger fourth quarter and full-year adjusted EBITDA around break-even.
Bearish
  • − APAC revenue, including China, fell 25% year over year, although it increased 5% sequentially from Q2.
  • − Biopharma distributor and CRO revenue declined approximately 17% to $28.7 million, and product revenue fell 3%.
  • − Adjusted EBITDA fell to $0.7 million from $2.5 million.
  • − The jury found infringement under the doctrine of equivalents on the fourth patent claim, and the company is pursuing remedies.
  • − General and administrative expense increased 14%, primarily because of higher litigation-related expenses.
  • − Implementation of the new business-unit structure was postponed until the start of 2027 because the mid-year transition was viewed as too risky.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +26%
above
Price vs 50-day avg +6%
above
RSI (14) 55
neutral
MACD trend Negative
52-week position 87%
near high
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +41%
trailing
YTD return +17%
this year
Relative strength +45%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.14% of shares out · ▼ -6.9% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
152 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Strong
Revenue growth +6414%
Y/Y
Gross margin 54%
contracting
EPS growth −550%
Y/Y
Free cash flow $-8.8M
Buyback $35.0M
remaining
Balance sheet $90.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 52%
annualized · 1-yr
Max drawdown −43%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 4
Latest guidance · from the 8-K filed Nov 4, 2026
Total revenue guidance · full year 2026 Maintained $208M – $211M
Aug 5, 2026 $207M – $212M changed to Nov 4, 2026 $208M – $211M
prior FY $201.49M midpoint +4.0% Y/Y
Prior guidance period ended · from the 8-K filed Jan 13, 2026
Total revenue · full year 2025 $201M
Revenue · fourth quarter of 2025 $62M
Guided vs delivered · last 4 settled
Full year 2025 revenue full year 2025
guided $196M – $205M
$201.49M In line
Full year 2024 revenue full year 2024
guided $203M – $210M
$200.45M Miss −2.9%
Full year revenue full year 2023
guided $188M – $192M
$193.02M Beat +1.6%
Revenue full year 2022
guided $160M – $168M
$2.96M Miss −98.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+26% Bullish
Price vs 50-day avg
+6% Bullish
RSI (14)
55 Neutral
MACD trend
Negative Bearish
52-week position
87% Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Distributing
-1% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.14% of shares out · ▼ -6.9% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
152 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $6 · 87% Range high $6
vs 200-day avg +26% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $1.5M Q2 2026 —
Net new units added 142 Q2 2026 —
Non-GAAP adjusted gross margin non-GAAP 56% Six Months Ended June 30, 2026 —
Non-GAAP adjusted gross profit non-GAAP $52.04M Six Months Ended June 30, 2026 —
Total installed base 3,933 Q2 2026 —
Total recurring revenue $18.5M Q2 2026 —
Trailing-12-month recurring revenue as a percentage of total revenue 35% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CTKB
Cytek Biosciences, Inc.
this stock
$774.24M +17.2% +6414.2% — 3.1%
ABT
Abbott Laboratories
$180.95B -16.6% +5.7% 39.0 1.1%
MDT
Medtronic plc
$128.83B +4.9% +8.4% 24.8 1.8%
SYK
Stryker Corp
$121.12B -9.5% +11.2% 33.9 1.7%
BSX
Boston Scientific Corp
$63.26B -54.2% +12.5% 18.5 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
152
% held
66.4%
Net QoQ
+5.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
153
View
Short & Settlement
Short Interest Falling
Shares short
4.1M
Days to cover
3.6d
Change
-303.8K sh
View
Short Volume
Short vol %
45%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
262
Value
$1.5K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
31.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$201.5M
Net income (FY)
$-66.5M
EPS diluted
$-0.09
View
Buybacks
Authorized
$50.0M
Remaining
$35.0M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
20

Cytek's analyzer category sales were up more than 30% compared to a year ago, and gross margin improved 600 basis points from the Singapore manufacturing shift, lower tariffs and better material costs.

View
Proposed Sales
Value
$146.5K
Shares
31.7K
Filed
Sep 2, 2026
View
Exempt Offerings
Offering
$120.0M
Filed
Nov 10, 2020
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Cytek Biosciences to Participate…
Published
Nov 18, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
CTKB +2.8% +7.6% +41.3% -3.4% +17.2%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +6.7% +13.2% +44.8% -0.1% +10.2%

Capital returns

Buyback program · as of Dec 31, 2025
Authorized
$50.00M
Spent (derived)
$15.00M
Remaining
$35.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1831915 CUSIP 23285D109 13F (30d) 155 filings 138 filers Visit website Investor relations